NCT05577182View on ClinicalTrials.gov

Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

August 3, 2026

Study Completion Date

August 3, 2026

Conditions
Advanced Malignancies
Interventions
DRUG

INCA32459-101

solution for infusion

Trial Locations (13)

28041

Hospital Universitario 12 de Octubre, Madrid

28050

Centro Integral Oncologico Clara Campal, Madrid

28223

Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón

37134

Centro Ricerche Cliniche Di Verona (Crc), Verona

77030

University of Texas Md Anderson Cancer Center, Houston

90025

The Angeles Clinic and Research Institute, Los Angeles

01200

Cliniques Universitaires Ucl Saint-Luc, Brussels

02650

Universitair Ziekenhuis Antwerpen (Uza), Edegem

09000

Universitair Ziekenhuis Gent, Ghent

01090

Universitair Ziekenhuis Brussel, Jette

05530

Chu Ucl Namur University Hospital Mont-Godinne, Yvoir

08023

Hospital Quironsalud Barcelona, Barcelona

08906

Ico Institut Catala D Oncologia, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT05577182 - Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | Biotech Hunter | Biotech Hunter